Table 1.
Baseline Characteristics of the study population, stratified by no statin at followup or use of statin at follow-up.
| All Subjects (N=3153) |
No Statin (N=2237) |
Incident Statin Use (N=916) |
P-Value | |
|---|---|---|---|---|
| Age (y) | 59.0 [51.0–68.0] | 58.0 [50.0–68.0] | 61.0 [54.0–69.0] | <0.0001 |
| Male Gender | 1384 (43.9) | 992 (44.3) | 392 (42.8) | 0.43 |
| Race | 0.004 | |||
| White | 1235 (39.2) | 834 (37.3) | 401 (43.8) | |
| Asian | 394 (12.5) | 297 (13.3) | 97 (10.6) | |
| Black | 855 (27.1) | 627 (28.0) | 228 (24.9) | |
| Hispanic | 669 (21.2) | 479 (21.4) | 190 (20.7) | |
| Weight (lb) | 165.7 [143.0–192.0] | 165.0 [142.3–190.0] | 168.0 [144.1–194.9] | 0.02 |
| BMI (kg/m2) | 27.0 [24.1–30.3] | 26.8 [23.9–30.2] | 27.5 [24.6–30.9] | <0.0001 |
| Waist Circumference (cm) | 95.0 [86.0–103.5] | 94.2 [85.2–102.9] | 96.5 [87.6–105.0] | <0.0001 |
| Systolic BP (mmHg) | 120.3 [108.0–136.0] | 118.5 [107.0–134.5] | 124.5 [112.5–140.0] | <0.0001 |
| Diastolic BP (mmHg) | 71.5 [64.5–78.0] | 71.0 [64.5–77.5] | 72.5 [65.5–79.0] | <0.0001 |
| Hypertension | 1116 (35.4) | 693 (31.0) | 423 (46.2) | <0.0001 |
| Antihypertensive Rx | 838 (26.6) | 514 (23.0) | 324 (35.4) | <0.0001 |
| Smoking Status | 0.19 | |||
| Never | 1678 (53.2) | 1181 (52.8) | 497 (54.3) | |
| Former | 1099 (34.9) | 774 (34.6) | 325 (35.5) | |
| Current | 375 (11.9) | 281 (12.6) | 94 (10.3) | |
| Family history of diabetes | 1062 (33.7) | 726 (32.5) | 336 (36.7) | 0.02 |
| Metabolic Syndrome | 644 (20.4) | 390 (17.4) | 254 (27.7) | <0.0001 |
| Glucose (mg/dl) | 86.0 [81.0–91.0] | 86.0 [80.0–91.0] | 87.0 [81.0–91.0] | 0.002 |
| CRP (mg/l) | 1.7 [0.8–4.0] | 1.6 [0.7–3.8] | 2.0 [1.0–4.6] | <0.0001 |
| Exercise (MET•min/week) | 885.0 [210.0–2100.0] | 870.0 [180.0–2100.0] | 907.5 [210.0–2100.0] | 0.8 |
| Coronary Calcium | ||||
| Agatston Score | 0.0 [0.0–36.7] | 0.0 [0.0–23.0] | 1.6 [0.0–105.8] | <0.0001 |
| CAC=0 | 1863 (59.1) | 1410 (63.0) | 453 (49.5) | <0.0001 |
| CAC 1–100 | 745 (23.6) | 517 (23.1) | 228 (24.9) | |
| CAC>100 | 545 (17.3) | 310 (13.9) | 235 (25.7) | |
| Liver Attenuation (HU) | 62.5 [57.5–67.5] | 63.0 [58.0–67.5] | 62.0 [56.0–67.5] | 0.003 |
| Fatty Liver (≤40 HU) | 146 (4.6) | 86 (3.8) | 60 (6.6) | 0.001 |
| Maximum Stain Intensity | <0.0001 | |||
| No Statin | 2237 (70.9) | 2237 (100.0) | 0 (0.0) | |
| Statin of Unknown Intensity | 6 (0.2) | 0 (0.0) | 6 (0.7) | |
| Low-Intensity Statin | 145 (4.6) | 0 (0.0) | 145 (15.8) | |
| Moderate-Intensity Statin | 652 (20.7) | 0 (0.0) | 652 (71.2) | |
| High-Intensity Statin | 113 (3.6) | 0 (0.0) | 113 (12.3) |
Abbreviations: Hx=history, HU=Hounsfield units. Covariates are reported in the population available.